$BCDA News

BioCardia Announces Presentation Of Data From CardiAMP Minimally-Invasive Chronic Myocardial Ischemia Treatment Trial Demonstrating Positive Clinical Outcomes

BioCardia, Inc. (BCDA) Q1 2026 Earnings Call Transcript

BioCardia Q1 2026 Earnings Call: Complete Transcript

BioCardia Inc (NASDAQ:BCDA) Q1 Earnings Miss Overshadows Clinical Progress

BioCardia Q1 EPS $(0.21) Misses $(0.17) Estimate

BioCardia Says FDA Raised No Safety Concerns, Outlines Two Clearance Pathways For Helix Catheter System

BioCardia Announces Allowance Of Japanese Patent Titled "Target Site Selection, Entry, and Update with Automatic Remote Image Annotation."

BioCardia Announces Allowance Of Japanese Patent Titled "Target Site Selection, Entry, and Update with Automatic Remote Image Annotation."

Japan's Pharmaceutical and Medical Device Agency Finds BioCardua's CardiAMP Cell Therapy Sufficient To Support Market Clearance

BioCardia Files Request For FDA Meeting Related To Approval For CardiAMP System For Ischemic Chronic Heart Failure

BioCardia, Inc. Q4 2025 Earnings Call Summary

BioCardia Inc (BCDA) Q4 2025 Earnings Call Highlights: Promising Clinical Results Amid ...

BioCardia, Inc. 2025 Q4 - Results - Earnings Call Presentation

BioCardia, Inc. (BCDA) Q4 2025 Earnings Call Transcript

BioCardia Reports 2025 Business Highlights and Financial Results

BioCardia Q4 EPS $(0.06) Beats $(0.17) Estimate

BioCardia to Host 2025 Financial Results and Corporate Update Conference Call on March 24, 2026

BioCardia Announces Pre-Submission Approval Package for Helix Transendocardial Delivery Catheter Accepted by FDA

The FDA Accepts Biocardia's Pre-submission Package For The Approval Of Its Helix Transendocardial Delivery Catheter Intended For Intramyocardial Therapeutic And Diagnostic Agent Delivery

BioCardia Late Breaking Echocardiography Clinical Results from CardiAMP HF Trial Presented at Technology and Heart Failure Therapeutics (THT)